Similar articles

• Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.

  Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, Villamil FG, Andreone P, George J, Dammers E, Fu M, Kurland D, Lenz O, Ouwerkerk-Mahadevan S, Verbinnen T, Scott J, Jessner W. Reddy KR, et al. Lancet Infect Dis. 2015 Jan;15(1):27-35. doi: 10.1016/S1473-3099(14)71002-3. Epub 2014 Dec 5. Lancet Infect Dis. 2015. PMID: 25482330 Clinical Trial.
• Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C.

  Maekawa S, Enomoto N. Maekawa S, et al. J Gastroenterol. 2014 Jan;49(1):163-4. doi: 10.1007/s00535-013-0926-7. Epub 2013 Dec 21. J Gastroenterol. 2014. PMID: 24356811 No abstract available.
• The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.

  Pearlman BL, Ehleben C, Perrys M. Pearlman BL, et al. Gastroenterology. 2015 Apr;148(4):762-70.e2; quiz e11-2. doi: 10.1053/j.gastro.2014.12.027. Epub 2014 Dec 31. Gastroenterology. 2015. PMID: 25557952 Clinical Trial.
• Simeprevir for the treatment of chronic hepatitis C genotype 1 infection.

  Takehara T. Takehara T. Expert Rev Anti Infect Ther. 2014 Aug;12(8):909-17. doi: 10.1586/14787210.2014.925800. Epub 2014 Jun 2. Expert Rev Anti Infect Ther. 2014. PMID: 24882512 Review.
• Simeprevir for the treatment of chronic hepatitis C.

  You DM, Pockros PJ. You DM, et al. Expert Opin Pharmacother. 2013 Dec;14(18):2581-9. doi: 10.1517/14656566.2013.850074. Epub 2013 Oct 19. Expert Opin Pharmacother. 2013. PMID: 24138198 Review.